Construction of chondroitin sulfate microarray - project title: construction of chondroitin sulfate microarray the proposal is aimed to develop a high throughput method to study the interactions…

Ended Project Grant Awarded Last action

Award ID
R43GM140693
Recipient
Awarding agency
Obligated
$663,268

Award facts

Assistance listing
93.859 Biomedical Research and Research Training
Completion date
Place of performance
Raleigh, NC 27606, USA

Award details come from USAspending.gov.

Description

Construction of chondroitin sulfate microarray - project title: construction of chondroitin sulfate microarray the proposal is aimed to develop a high throughput method to study the interactions between chondroitin sulfate (CS) and proteins. CS is a member of glycosaminoglycan family displaying a wide range of biological functions. Glycan therapeutics is a company specialized in CS and other glycosaminoglycan related research products. In this phase I sbir proposal, a CS microarray technique will be constructed. The strength of the company is capable of synthesizing structurally defined CS oligosaccharides using the enzymatic method, allowing to synthesize gram-scale of CS oligosaccharide. A single specific aim is proposed in the current application, which to build CS-microarray analysis technique covering 30 different oligosaccharides. Three experiments to support the quality control of the technology are proposed. First experiment is to couple a chemical linker to the synthesized CS oligosaccharides to allow affixation of the oligosaccharides on the array chip. Second experiment is to prepare eight fluorescently labeled CS oligosaccharides to evaluate the efficiency for the affixation to the chip. Third experiment is to identify a CS-binding protein to serve as a positive control for the CS-microarray analysis. In the phase II studies, the number of oligosaccharides array slides will be expanded to 200 to fully represent the structures of CS isolated from natural sources. The success will lead to a convenient approach for improving research in glycosciences.

Transactions

Action Obligated Date
Amendment $0
Amendment $331,634
Original award $331,634

Quick answers

Who received award R43GM140693?

R43GM140693 was awarded to Glycan Therapeutics Corporation by National Institute of General Medical Sciences (National Institutes of Health) on May 1, 2022.

How much is award R43GM140693 worth?

$663,268 has been obligated on R43GM140693.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award